VIEWPOINTS

Stephen Pagnotta Shares Insights on the US FDA Approval of the Cyltezo Pen, a New Autoinjector Option for Cyltezo

Shots: Stephen gave a brief introduction about Cyltezo (an FDA-approved interchangeable Humira biosimilar) and spoke about the features of the Cyltezo Pen (a new autoinjector) approved by the US FDA He also gave a comparative view of the Cyltezo Pen vs. the conventional Cyltezo PFS. He also talked about how BI is informing and educating…

September 5, 2023

Michael Jones Shares his Views on the Closing of Acquisition of Apollo Endosurgery

Shots: Michael discussed the closure of its acquisition of Apollo Endosurgery. He emphasized how this acquisition will broaden Boston Scientific's ELS portfolio, particularly in closure and suturing, while entering the endobariatric market He also talked about how the Apollo Endosurgery products will be integrated into Boston Scientific's existing endoluminal surgery (ELS) portfolio The interview shows…

September 4, 2023

Eli Khankin Shares Update on the P-III IMAGINE Study Protocol Published in American Journal of Transplantation

Shots: Eli spoke about the P-III IMAGINE study protocol evaluating Clazakizumab along with 6 articles by several experts published in the American Journal of Transplantation Eli then talked about Clazakizumab's potential mechanism of action currently under investigation The interview shows how CSL Behring works to develop and deliver innovative therapies for people living with conditions in…

August 31, 2023

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

Shots: Robert spoke about the topline data from the P-II study evaluating Lysergide. The data was unleashed by MindMed collaborators at the University Hospital Basel and the University Hospital of Psychiatry The data demonstrated significant, rapid, durable and beneficial effects of Lysergide and its potential to mitigate symptoms of MDD. He also discussed how these…

August 29, 2023

Curtis Rambaran’s Insights from Zerlasiran P-II Study for Patients with Elevated Lipoprotein (a) at High-Risk ASCVD Events

Shots: Curtis gave a brief introduction about Zerlasiran. He also talked about the study design and the results from the P-II trial (ALPACAR-360) under which Zerlasiran is being evaluated He also highlighted how Zerlasiran can differ from other therapies that are in development to treat elevated lipoprotein (a) at high risk of atherosclerotic cardiovascular disease (ASCVD)…

August 28, 2023

Dr. Beth McQuiston Shares her Views on the US FDA Clearance of the First Concussion Blood Test Available for Lab Instruments

Shots: Dr. Beth discussed traumatic brain injuries (TBIs) and the new TBI blood test by Abbott. She told PharmaShots how this blood test measures specific biomarkers, offering objective results within 12 hours, and aiding in evaluating suspected mild TBIs She also talked about how Abbott’s Alinity i lab technology facilitates swift testing, complementing Abbott's i-STAT…

August 21, 2023

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Shots: Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CT He also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…

August 17, 2023

Marija Geertsen, Vice President, U.S. Medical Affairs, Lundbeck Shares Insights from 12 Abstracts Presented at AAN 2023

Shots: Marija spoke about the data on Migraine and Brain Health presented at the 75th Annual Meeting of the AAN 2023. The 12 abstracts included the data from post-hoc and real-world analyses of VYEPTI She also talked about a medical symposium sponsored by the company “Migraine: Your Patient, Your Partner. Proactive care for high-frequency, worsening…

August 14, 2023

Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New SPINRAZA (nusinersen) Long-Term Data in SMA

Shots: Kathleen spoke about new long-term SPINRAZA (nusinersen) data presented at the 3rd International Scientific Congress She then explained the new findings from individuals with infantile-onset SMA who were treated with SPINRAZA in the pivotal ENDEAR study followed by the long-term extension SHINE study for up to 7 years The interview also discusses Biogen’s advances…

August 7, 2023

Mary Rodgers, Principal Research Scientist at Abbott Shares Insights on its Partnership with CLIMADE Consortium to Predict Disease Outbreaks Caused by Climate Change

Shots: Mary talked about Abbott's partnership Climate Amplified Disease and Epidemics (CLIMADE) consortium will use data science to predict, track and control diseases that may be amplified by climate change She then spoke about how Abbott and its partners in the Abbott Pandemic Defense Coalition will provide viral sequencing and testing data as part of…

August 3, 2023